Tesamorelin: The Complete Guide
A 44-amino-acid synthetic version of the body's natural GHRH — the only GHRH analogue with full FDA approval, supported by multiple Phase 3 trials. Works through the same pathway as natural GHRH, with engineered stability to last long enough to do meaningful work.
What is Tesamorelin?
Here is the simplest way to understand Tesamorelin: where CJC-1295 is a shortened version of natural GHRH (just the first 29 amino acids of the original 44), Tesamorelin uses the full 44-amino-acid structure of natural GHRH — with one small modification at the front to make it last long enough to be useful. Both compounds talk to the pituitary through the same GHRH receptor. Tesamorelin just preserves more of the original message.
The modification is a fatty acid group called trans-3-hexenoic acid attached to the N-terminus of the peptide. Research suggests this small chemical addition serves two purposes — it shields the peptide from the enzymes (DPP-IV in particular) that would normally chew through GHRH within minutes, and it helps the peptide grip the GHRH receptor more tightly. Together, these changes turn natural GHRH from a hormone that breaks down too fast to use into a research compound that lasts long enough to produce measurable effects.
What sets Tesamorelin apart in the growth hormone research family is its clinical evidence base. Tesamorelin was developed by Theratechnologies in Canada and received FDA approval in 2010 — making it the only GHRH analogue with full regulatory approval anywhere in the world. The original approved indication was HIV-associated lipodystrophy, a specific condition in which antiretroviral therapy can produce abnormal fat redistribution. This produces something most research peptides never achieve: multiple Phase 3 clinical trials, established safety data, and a well-documented mechanism in human subjects. The same evidence base also makes Tesamorelin a particularly clean research tool for any work involving the GH axis.
Research Applications
Research on Tesamorelin spans the GHRH axis pharmacology with a substantial human clinical trial base, the visceral-adipose-tissue findings from the HIV-associated lipodystrophy trial program that supported the original FDA approval, and emerging research on liver fat, metabolic markers, and brain health.
Research describes approximately 15% reduction in visceral adipose tissue measurements over 26 weeks in the HIV-associated lipodystrophy trial program that supported the FDA approval. The selectivity for visceral over subcutaneous tissue is research-suggested to relate to higher GH receptor density in visceral tissue.
Research suggests Tesamorelin works upstream — it tells the pituitary to release the body's own growth hormone through the natural GHRH pathway. The hypothalamic-pituitary feedback loop stays intact, somatostatin still regulates release, the system does not get bypassed the way it does with direct synthetic GH administration.
Beyond the visceral-adipose-tissue findings, research describes effects on cholesterol, triglycerides, and other cardiovascular risk markers in research subjects. The metabolic effects appear to extend beyond the headline adipose-tissue finding.
Emerging research is examining whether Tesamorelin affects cognitive function. The growth hormone axis is increasingly recognised as playing a role in brain health, and Tesamorelin's well-characterised mechanism makes it a clean research tool for this work.
First FDA approval came in 2010 for HIV-associated lipodystrophy, supported by multiple Phase 3 trials — a level of regulatory and clinical evidence most research peptides will never achieve. The approval produces extensive human safety data, established pharmacokinetic profiles, and well-documented outcome measures.
Research is examining whether Tesamorelin reduces liver fat (hepatic steatosis) — one of the fastest-growing research areas in metabolic disease. Stanley et al. 2014 (JAMA) is the foundational paper in this area, examining liver fat alongside visceral fat in research subjects.
How Tesamorelin Works
The big-picture answer first: Tesamorelin binds to the GHRH receptor on pituitary cells — the same receptor that natural GHRH uses — and triggers the release of growth hormone. Research suggests the natural pulsatile pattern of GH release is preserved, the body's feedback systems stay intact, and the GH that gets released then drives the downstream effects on body composition.
GHRH receptor binding: Tesamorelin reaches the GHRH receptor on somatotroph cells in the anterior pituitary — the cells that produce growth hormone. The trans-3-hexenoic acid modification at the front of the peptide does two things research suggests are critical: it shields the peptide from rapid breakdown by DPP-IV and other enzymes that would normally clear GHRH within minutes, and it improves the peptide's grip on the receptor itself. Both modifications extend the time the signal lasts.
Pulsatile GH release — the institutional honesty point: the way Tesamorelin works is different from injecting synthetic growth hormone directly. Direct GH bypasses every regulatory mechanism evolution built into the GH axis — somatostatin can no longer slow release down, the hypothalamic feedback loop has nothing to feed back into, the natural pulse pattern is replaced by whatever continuous level the injection produces. Research suggests Tesamorelin works upstream of all this. It tells the pituitary to release GH, but the pituitary still controls the timing and quantity. Somatostatin can still suppress release if levels rise too high. The natural pulsatile pattern is preserved.
Downstream effects on visceral fat: the GH released by Tesamorelin binds to growth hormone receptors on tissues throughout the body. Research suggests visceral adipose tissue (the deep belly fat) has higher GH receptor density than subcutaneous fat, which is part of why the fat-reduction effects appear concentrated there rather than evenly distributed. GH receptor activation in fat cells triggers lipolysis (fat breakdown), and research suggests sustained activation over weeks produces the visceral fat reductions documented in the Phase 3 trials.
The bioavailability paradox: Tesamorelin has only about 4% bioavailability after subcutaneous injection, and the peptide clears from plasma in about 26 minutes. This sounds like a problem until you understand the pharmacology. Research suggests the GH pulse Tesamorelin triggers, and the IGF-1 elevation that follows, persist for hours to days — much longer than the peptide itself stays in circulation. Research protocols need to account for this disconnect between how long the peptide is detectable and how long its effects last.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Falutz J, Allas S, Blot K, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” The New England journal of medicine, 2007. PubMedThe pivotal Phase 3 trial in NEJM that supported the original FDA approval. Established the visceral fat reduction effect (~15% over 26 weeks) and the safety profile in the approved patient population. The most important single paper for understanding the clinical evidence base.
- Stanley TL, Feldpausch MN, Oh J, et al. “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.” JAMA, 2014. PubMedExtended the visceral-fat findings to liver fat (hepatic steatosis) — the foundational paper for the fatty-liver research lane. Important for understanding how Tesamorelin's effects extend beyond the headline visceral-fat finding into broader metabolic research.
- Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” Drugs, 2011. PubMedA comprehensive review summarising the clinical evidence base, mechanism of action, pharmacokinetics, and safety profile. Useful as a single starting point for understanding the full Tesamorelin clinical research record.
- Spooner LM, Olin JL. “Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.” The Annals of pharmacotherapy, 2012. PubMedA clinical-pharmacology focused review with detailed treatment of the pharmacokinetic and pharmacodynamic profile — useful for understanding the bioavailability/half-life paradox and how the peptide produces effects that outlast its own circulation time.
Browse all Tesamorelin research on PubMed →
Related Research Guides
More in Growth Hormone & Endocrine
The shorter-acting GHRH analogue in the same cluster — 29 amino acids instead of Tesamorelin's full 44-amino-acid structure, with less extensive clinical evidence but a similar mechanism through the same GHRH receptor.
Read guide →Selective GH SecretagogueThe Growth Hormone cluster sibling working on a different pathway — the ghrelin receptor instead of the GHRH receptor. Both target the same pituitary cells but through different doors, and research suggests the two pathways are complementary.
Read guide →HGH FragmentA growth hormone fragment that isolates fat metabolism without engaging the broader GH-release pathway. Different mechanism than Tesamorelin entirely — works downstream of GH on adipose tissue rather than upstream at the GHRH/pituitary level.
Read guide →